1. Home
  2. CASI vs NEUP Comparison

CASI vs NEUP Comparison

Compare CASI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CASI Pharmaceuticals Inc.

CASI

CASI Pharmaceuticals Inc.

HOLD

Current Price

$0.94

Market Cap

19.7M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.22

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASI
NEUP
Founded
1991
1996
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.7M
21.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CASI
NEUP
Price
$0.94
$4.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.00
$21.00
AVG Volume (30 Days)
49.1K
51.2K
Earning Date
11-14-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,846,000.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.72
N/A
52 Week Low
$0.75
$3.27
52 Week High
$3.09
$21.40

Technical Indicators

Market Signals
Indicator
CASI
NEUP
Relative Strength Index (RSI) 46.10 52.15
Support Level $0.94 $3.98
Resistance Level $1.01 $4.18
Average True Range (ATR) 0.11 0.20
MACD 0.01 0.07
Stochastic Oscillator 30.03 65.04

Price Performance

Historical Comparison
CASI
NEUP

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: